Evidence map›Paper›PMID 29508228›Full record

ArticleInternational journal of hematology2018

T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.

Hideki Sano, Kazuhiro Mochizuki, Shogo Kobayashi, Yoshihiro Ohara, Masaki Ito, Tomoko Waragai, Nobuhisa Takahashi, Kazuhiko Ikeda, Hitoshi Ohto, Atsushi Kikuta

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Graft CD8International journal of hematology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hideki SanoDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.ORCID http://orcid.org/0000-0002-3242-6917
Kazuhiro MochizukiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Shogo KobayashiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Yoshihiro OharaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Masaki ItoDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Tomoko WaragaiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Nobuhisa TakahashiDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Kazuhiko IkedaDepartment of Blood Transfusion and Transplantation Immunology, Fukushima Medical University Hospital, Fukushima, Japan.
Hitoshi OhtoDepartment of Blood Transfusion and Transplantation Immunology, Fukushima Medical University Hospital, Fukushima, Japan.
Atsushi KikutaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan. akikuta@fmu.ac.jp.
Fukushima Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the efficacy and toxicity of T-cell-replete haploidentical stem cell transplantation (TCR-haploSCT) using low-dose antithymocyte globulin (ATG) in children with refractory/relapsed (R/R) acute leukemia. From October 2009 to April 2016, 39 consecutive patients with R/R acute leukemia who underwent TCR-haploSCT were included. At the time of TCR-haploSCT, 17 patients were in complete remission (CR), but 22 had active disease. Thirty-three patients received a myeloablative regimen and six received a reduced-intensity conditioning regimen. Graft-versus-host disease (GvHD) prophylaxis comprised tacrolimus, methotrexate, prednisolone, and low-dose ATG (thymoglobulin 2.5 mg/kg). Neutrophil engraftment (> 0.5 × 10

Indexed as

AdolescentAntilymphocyte SerumChildChild, PreschoolFemaleFollow-Up StudiesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsInfantLeukemia, Myeloid, AcuteMaleMethotrexatePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisoloneAntilymphocyte SerumImmunosuppressive AgentsMethotrexatePrednisoloneTacrolimusAcute leukemiaChildrenGraft-versus-host diseaseHaploidentical hematopoietic stem cell transplantationRelapse

Identifiers

PMID29508228
OpenAlexW2789996991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.